New Triple-Drug attack on blood cancer begins human testing
NCT ID NCT07490288
Summary
This early-stage study is testing the safety and initial effectiveness of a new three-drug combination (called VAM) for adults newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. The study will enroll 30 participants who are eligible for strong chemotherapy. The goal is to see if this combination can help patients achieve remission and control the disease, with some patients also receiving a stem cell transplant if needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.